Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
Alterity Therapeutics Limited develops treatments for neurodegenerative diseases, with a clinical program centered on Multiple System Atrophy and related Parkinsonian disorders. News about ATHE commonly covers ATH434, its lead MSA candidate, Phase 2 analyses, FDA interactions, chemistry, manufacturing and control updates, and presentations at neurology and imaging conferences.
Coverage also includes bioMUSE Natural History Study biomarker work, including quantitative susceptibility mapping MRI for iron dysregulation in MSA, Appendix 4C cash flow and corporate updates, board appointments, and discussions of the company’s drug discovery platform for patentable chemical compounds targeting neurological disease pathology.
Alterity Therapeutics (NASDAQ: ATHE) released its Q4 FY24 Quarterly Cash Flow Report, highlighting positive interim data from the ATH434-202 Phase 2 clinical trial for Multiple System Atrophy (MSA). The trial showed improvement in daily living activities and stable or improved neurological symptoms in some patients. The bioMUSE Natural History Study continues to inform Alterity's Phase 2 trials, characterizing early-stage MSA.
Key points:
- Cash balance of A$12.6M as of June 30, 2024
- Positive interim data from ATH434-202 Phase 2 trial
- Ongoing ATH434-201 Phase 2 trial for early-stage MSA
- Presentations at World Orphan Drug Congress and American Academy of Neurology Annual Meeting
- Promising results from bioMUSE study guiding patient selection and endpoints for Phase 2 trials
Alterity Therapeutics (NASDAQ: ATHE), a biotechnology company focused on developing treatments for neurodegenerative diseases, has announced an upcoming investor webinar. The event, hosted by MST Financial, is scheduled for July 25, 2024, at 8:30 AM AEST (July 24, 2024, at 6:30 PM ET).
CEO David Stamler will present recent company developments, including interim data from the Phase 2 open-label study of ATH-434 (202). Investors and shareholders can register for the Zoom webcast and will have the opportunity to ask questions following the presentation.
This webinar provides a platform for Alterity to share its progress in developing disease-modifying treatments and engage with its investor community.
Alterity Therapeutics (NASDAQ: ATHE) has reported positive interim data from its ATH434-202 Phase 2 clinical trial for multiple system atrophy (MSA). Key findings include:
- 43% of participants showed improvement in daily living activities
- 29% had stable or improved neurological symptoms
- Objective biomarkers demonstrated improvement consistent with clinical findings
- ATH434 was well-tolerated with no safety signals detected
The interim analysis included data from 7 participants treated for 6 months and neuroimaging data from 3 participants treated for 12 months. Clinical responders showed reduced iron accumulation in key brain areas and stable levels of NFL, a marker of axonal injury. These results suggest ATH434's potential to modify the course of MSA, particularly in less advanced cases.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) will present at the MST Access ‘Hidden Gems in Life Sciences’ webinar. The presentation, led by CEO David Stamler, will provide an overview of the company's initiatives in developing treatments for neurodegenerative diseases. The webinar will take place on June 13, 2024, in Australia (1:30 p.m. AEST) and June 12, 2024, in the United States (8:30 p.m. PT/11:30 p.m. ET). Investors can register to join the presentation and ask questions during the event. A recording will be available on Alterity's website post-event.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) will host an investor webcast to discuss new data from the bioMUSE Natural History Study and its implications for the ATH434-202 Phase 2 trial endpoints. The webcast, set for May 29, 2024, in the U.S. and May 30, 2024, in Australia, will feature CEO Dr. David Stamler and Professor Daniel Claassen from Vanderbilt University. Dr. Claassen, a key opinion leader and principal investigator, will provide insights into the study results and their impact. Registration is required to attend the webcast, where investors can ask questions.
Alterity Therapeutics, a biotechnology company, received positive feedback from the Data Monitoring Committee regarding the Phase 2 clinical trial of ATH434 for the treatment of multiple system atrophy (MSA). The trial is progressing as planned, with top-line data expected in January 2025. The study aims to demonstrate the drug's efficacy, safety, and target engagement through various assessments.
Alterity Therapeutics released its Q3 FY24 Quarterly Cash Flow Report, showcasing promising Phase 2 baseline data for ATH434-201 targeting biomarkers for slowing disease progression. The company raised A$5.25M, received a A$3.9M tax incentive refund, and ended the quarter with A$18.3M in cash. Operational updates include positive DMC review for ATH434-201, presentations at AAN, enrollment progress for ATH434-202, and promising results for ATH434 in Parkinson's disease. The bioMUSE study continues to provide valuable data on MSA progression.
Alterity Therapeutics presented new data at the World Orphan Drug Congress USA 2024 demonstrating the potential of ATH434 to treat Friedreich's Ataxia. The study showed that ATH434 acts as an iron chaperone, redistributing iron in the body, which could help reduce labile iron levels and slow disease progression. The unique iron-binding properties of ATH434 set it apart from traditional iron chelators, making it a promising treatment for neurodegenerative diseases.
Summary not available.
Summary not available.